Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Heart Test Laboratories Inc. Common Stock (HSCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/02/2025: HSCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.96M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta 2.58 | 52 Weeks Range 2.36 - 5.30 | Updated Date 06/29/2025 |
52 Weeks Range 2.36 - 5.30 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.95% | Return on Equity (TTM) -163.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4347199 | Price to Sales(TTM) 202.07 |
Enterprise Value 4347199 | Price to Sales(TTM) 202.07 | ||
Enterprise Value to Revenue 46.26 | Enterprise Value to EBITDA -0.14 | Shares Outstanding 1080950 | Shares Floating 995735 |
Shares Outstanding 1080950 | Shares Floating 995735 | ||
Percent Insiders 8.99 | Percent Institutions 2.17 |
Analyst Ratings
Rating 2 | Target Price 13 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Heart Test Laboratories Inc. Common Stock
Company Overview
History and Background
Heart Test Laboratories, Inc. (HSCS) is a medical technology company focused on preventing heart attacks. Founded in 2007, the company has developed a cardiac diagnostic technology aimed at providing early detection of heart disease.
Core Business Areas
- MyoVistau00ae: Electrocardiograph (ECG) device designed to detect subtle indicators of heart disease that may be missed by traditional ECGs.
- Research and Development: Continuous innovation and development of new features and applications for its cardiac diagnostic technology.
Leadership and Structure
Andrew Simpson is the Chief Executive Officer of Heart Test Laboratories, Inc. The company has a board of directors and a management team overseeing its operations, R&D, and commercialization efforts.
Top Products and Market Share
Key Offerings
- MyoVistau00ae: MyoVistau00ae is Heart Test Laboratories' primary product, a high-sensitivity ECG device designed to improve the early detection of heart disease. Market share data for MyoVistau00ae is not readily available due to the competitive nature of the diagnostics market and the company's relative size. Competitors include traditional ECG manufacturers and companies developing advanced cardiac diagnostic technologies. This is a direct sales product so revenue may include revenue from tests administered using the product.
Market Dynamics
Industry Overview
The cardiovascular diagnostics industry is experiencing growth due to an aging population, increasing prevalence of heart disease, and advancements in diagnostic technologies. The market includes ECG devices, stress tests, cardiac imaging, and blood tests.
Positioning
Heart Test Laboratories aims to differentiate itself with its MyoVistau00ae device, which is designed to provide more sensitive detection of heart abnormalities compared to traditional ECGs. Their competitive advantage lies in its proprietary technology and potential for early disease detection.
Total Addressable Market (TAM)
The global cardiac diagnostic market is estimated to be in the billions of dollars. Heart Test Laboratories is positioned to capture a portion of this market by focusing on early disease detection and offering a more sensitive diagnostic tool.
Upturn SWOT Analysis
Strengths
- Proprietary MyoVistau00ae technology
- Potential for early detection of heart disease
- Focus on innovation and R&D
Weaknesses
- Limited market share and brand recognition
- Dependence on MyoVistau00ae product line
- Requires significant capital for marketing and sales expansion
Opportunities
- Expansion into new markets and geographies
- Partnerships with hospitals and clinics
- Development of new applications for MyoVistau00ae technology
Threats
- Competition from established players in the cardiac diagnostics market
- Regulatory hurdles and approval processes
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- GE (GE)
- Siemens (SIEGY)
- Philips (PHG)
- Boston Scientific (BSX)
Competitive Landscape
Heart Test Laboratories faces strong competition from established medical device companies. Its competitive advantage lies in its proprietary technology, while its disadvantages include limited resources and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to determine due to the company's early stage and recent public offering.
Future Projections: Future growth is projected based on market adoption of MyoVistau00ae and expansion into new markets. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include securing regulatory approvals, expanding sales and marketing efforts, and developing new applications for MyoVistau00ae.
Summary
Heart Test Laboratories is a small company in the competitive cardiac diagnostic market. Its MyoVistau00ae technology offers potential for improved heart disease detection, but the company faces challenges in gaining market share and securing funding. Success hinges on effective marketing, strategic partnerships, and continued innovation to differentiate itself from larger competitors. Securing regulatory approvals and demonstrating clinical efficacy are also crucial for the company's long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Press Releases
- SEC Filings
- Market Research Reports (industry averages)
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Common Stock
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.